BCHE and early-onset autosomal dominant Alzheimer disease: Patients with probable DLB, particularly those with negative Alzheimer’s disease biomarkers show the best response to cholinesterase inhibitors.51 Because neurodegeneration in the nucleus basalis of Meynert is a characteristic of MCI-LB, patients with MCI-LB should be considered as candidates for cholinesterase inhibitor treatment.